Optimizing COPD Treatment In Portugal – Improving Health Outcomes And Reducing Treatment Costs In Patients with A History of Exacerbation with Indacatrol Plus Glycopyrronium

Abstract

A553CVD group compared to COPD patients without CVD (399€ vs. 361€ , p= 0.007). COPD related annual utilization of pharmaceuticals was higher in the CVD group (72.3% vs. 70.1%, p= 0.003), whereas AC for medications did not differ between groups (360€ vs. 346€ , p= 0.109). Neither COPD related hospital utilization (4.0% vs. 3.9%, p= 0.796), nor AC (156€ vs. 161€ , p= 0.779) differed between groups. ConClusions: Although this study is limited by a relatively short exposure time to CVD and observation period (360 days), comorbid CVD has an effect on COPD related sector specific annual utilization and direct medical costs. This indicates an intensified treatment need of COPD in the presence of CVD and the need for effective co-treatment strategies.